- Pfizer Inc (NYSE:PFE) has made a $15 million equity investment in Cardiff Oncology Inc (NASDAQ:CRDF) as part of the Pfizer Breakthrough Growth Initiative.
- Pfizer purchased 2.4 million shares of Cardiff Oncology's shares at $6.22 per share.
- Related: Why Are Investors Cheering Cardiff Oncology's New Data In Colorectal Cancer Setting?
- Cardiff will use the proceeds to advance its ongoing clinical programs in KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer and support onvansertib's development in additional indications.
- Additionally, the company has agreed to grant Pfizer rights of first access to data from its development programs.
- Price Action: CRDF shares are up 14.3% at $5.98 during the premarket session on the last check Thursday.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
